NeuroSense Therapeutics (NRSN) Q4 2025 earnings summary

Executive summary

• Advanced lead candidate PrimeC into late-stage clinical development with FDA-cleared Phase 3 program in ALS, following successful Phase 2b results and regulatory engagement.

• Demonstrated statistically significant survival benefit in ALS, with a 65% reduction in risk of death and over 14-month median survival advantage, published in JAMA Neurology.

• Expanded scientific visibility through conference presentations, new patents, and enhancement of the Scientific Advisory Board.

Financial highlights

• Research and development expenses increased 8.8% year-over-year to $6.2 million, mainly due to higher share-based payments and salaries.

• General and administrative expenses rose 16.6% year-over-year to $4.9 million, primarily from increased share-based compensation.

• Net loss for 2025 was $11.1 million, compared to $10.2 million in 2024.

• Cash position as of December 31, 2025 was approximately $0.2 million.

Outlook and guidance

• Upcoming milestones include additional biomarker readouts from PARADIGM, Phase 2 Alzheimer's study results, and a pre-NDS meeting with Health Canada in May 2026.

• Potential NDS submission in Canada and continued preparation for Phase 3 PARAGON trial in ALS.